Navigation Links
Aspreva obtains shareholder approval for acquisition by Galenica
Date:12/17/2007

VICTORIA, BC, Dec. 17 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Aspreva's shareholders and optionholders have approved the proposed acquisition of Aspreva by Galenica Group (SWX: GALN), through a wholly-owned Canadian subsidiary, at a price of US$26.00 per share in cash. At the special meeting of securityholders held this morning, the transaction was approved by over 99% of the votes cast by shareholders and by over 99% of the votes cast by shareholders and optionholders, voting together as a class.

The transaction is being carried out by way of a statutory plan of arrangement under Section 288 of the British Columbia Business Corporations Act. The closing of the transaction remains subject to final court approval, approval by the Minister of Industry under the Investment Canada Act, as well as the satisfaction or waiver of the conditions specified in the Combination Agreement entered into on October 17, 2007. An application for final court approval is scheduled to be heard by the British Columbia Supreme Court on December 18, 2007. Subject to court approval being obtained, receipt of approval by the Minister of Industry under the Investment Canada Act and the other conditions to closing being satisfied or waived, the transaction is expected to close on January 3, 2008.

Shareholders also today approved an amendment to Aspreva's shareholder rights plan in order to facilitate the proposed acquisition of Aspreva by Galenica Group.

Further details regarding the terms of the transaction are set out in Aspreva's management information circular dated November 15, 2007, which was filed by Aspreva on the Canadian SEDAR website at http://www.sedar.com and on the United States Securities and Exchange Commission's website at http://www.sec.gov.

Financial and Legal Advisors

Lazard Freres & Co. LLP and Lehman Brothers Inc. have acted as financial advisors to Aspreva with respect to the plan of arrangement. Aspreva's legal advisors are Farris, Vaughan, Wills & Murphy LLP, McCarthy Tetrault LLP and Cooley Godward Kronish LLP.

About Galenica

Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks. The Galenica Group enjoys a leading position in all its areas of activity - pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing. A large part of the Galenica's income is generated by international operations. For more information please visit http://www.galenica.com

About Aspreva

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Learn more about the company at http://www.aspreva.com

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable securities laws in Canada (collectively, "forward-looking statements"). The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: the potential acquisition of Aspreva by Galenica in an all cash transaction valued at USD$26.00 per outstanding share (the "Acquisition"); receiving approval from the Minister of Industry under the Investment Canada Act and receiving final approval for the Acquisition from the British Columbia Supreme Court.

With respect to the forward-looking statements contained in this news release, Aspreva has made numerous assumptions regarding, among other things: Galenica's ability to finance the Acquisition valued at USD$26.00 per outstanding share; the ability of Aspreva and Galenica to satisfy all of the closing conditions to complete the Acquisition; Aspreva's ability to protect its intellectual property rights and to not infringe on the intellectual property rights of others; and Aspreva's ability to comply with applicable governmental regulations and standards. Readers are cautioned that the plans, intentions or expectations disclosed in any forward-looking statements and underlying assumptions may not be achieved and that they should not place undue reliance on any forward-looking statement. Actual results or events could differ materially from the plans, intentions, expectations, and assumptions expressed or implied in any forward-looking statements as a result of numerous risks, uncertainties and other factors, including those relating to: the possibility of not satisfying all of the closing conditions to complete the Acquisition; risks related to integration of acquisitions; difficulties or delays in obtaining regulatory approvals; competition from other pharmaceutical or biotechnology companies; economic and capital market conditions; and currency exchange rates.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

CONTACT: Sage J. Baker, Vice President, IR & Corporate Communications, Aspreva Pharmaceuticals, (250) 708-4270, sbaker@aspreva.com


'/>"/>
SOURCE Aspreva Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Aspreva to Announce 2007 Third Quarter Results on October 31st
2. Aspreva Announces Preliminary Revenues for Third Quarter 2007
3. Aspreva to be Acquired by Galenica For US$915 Million
4. Aspreva Sends Materials for Special Meeting to be Held December 17
5. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
6. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
7. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
8. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
9. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
10. United Medicorp, Inc.s Shareholders Approve All Proposals
11. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown ... estimated to be $394.9 billion. The consequences of rapid innovation and growth are ... limits of technology, it is every business and individual’s job to give something back ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... and young adults, has kicked off its 4th annual Forum for Innovative Treatment ... theme is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
Breaking Medicine Technology: